Compass Pathways, a company developing a psychedelic treatment for depression, is looking to Johnson & Johnson's experience with its ketamine-based nasal spray Spravato as a template for its own potential launch. In an interview with BioPharma Dive, Compass executives said they hope to adopt the same strategy that helped establish Spravato in the market, should their drug receive FDA approval.
The approach pioneered by J&J involved building a network of certified treatment centers and supporting healthcare providers in administering the drug, which is not a typical at-home medication. While the source does not detail the exact components, Compass sees this as a viable path for its own product, which also requires supervised administration.
The plan underscores the growing interest in psychedelic therapies for mental health conditions. However, the source is a single interview, so there is no independent confirmation or contrasting perspective. The outcome depends on regulatory approval, which remains pending.